Hydroxystenozole

Hydroxystenozole (INN), also known as 17α-methylandrost-4-eno[3,2-c]pyrazol-17β-ol, is an orally active androgen/anabolic steroid (AAS) and a 17α-alkylated derivative of testosterone that was described in the literature in 1967 but was never marketed.[1] It is closely related to stanozolol (17α-methyl-5α-androstano[3,2-c]pyrazol-17β-ol), differing from it only in hydrogenation (i.e., double bonds and their placement).[1]

Hydroxystenozole

Clinical data
Other names	NSC-43194; 4-Dehydrostanozolol; 17α-Methyl-2'H-androsta-2,4-dieno[3,2-c]pyrazol-17β-ol
Routes of administration	By mouth
Drug class	Androgen; Anabolic steroid
ATC code	None
Identifiers
IUPAC name (1S,3aS,3bR,10aR,10bS,12aS)-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-tetradecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-ol
CAS Number	19120-01-5 Y 5697-57-4
PubChem CID	238684
ChemSpider	208502 Y
UNII	5OW19U0553
ChEBI	CHEBI:79555
ChEMBL	ChEMBL2105010 Y
CompTox Dashboard (EPA)	DTXSID70172642
Chemical and physical data
Formula	C21H30N2O
Molar mass	326.484 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CCC4=CC5=C(C[C@]34C)C=NN5
InChI InChI=1S/C21H30N2O/c1-19-11-13-12-22-23-18(13)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h10,12,15-17,24H,4-9,11H2,1-3H3,(H,22,23)/t15-,16+,17+,19+,20+,21+/m1/s1 N Key:OIIHTRLQCQVVQC-OBQKJFGGSA-N N
(verify)